Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Ivy gourd (Coccinia grandis) contains potent antidiabetic compounds including taraxerol, β-amyrin acetate, and cucurbitacin B that inhibit α-glucosidase enzymes with IC50 values as low as 0.75 μg/ml. These bioactive compounds enhance glucose uptake through GLUT4 recruitment and promote pancreatic β-cell regeneration for blood sugar regulation.
Reported Benefits (Provisional)
Origin & History
Ivy Gourd (Coccinia grandis) is a tropical vine belonging to the Cucurbitaceae family, producing small, edible fruits. It is native to the Indian subcontinent and Southeast Asia, thriving in warm, humid climates. This plant is highly valued in functional nutrition for its traditional use in metabolic and digestive support.
Research Narrative (Provisional)
Preclinical and some human clinical studies indicate Ivy Gourd's potential in blood sugar regulation, demonstrating improvements in glucose tolerance and insulin sensitivity. Research also supports its antioxidant and hypolipidemic effects, though more large-scale, randomized controlled trials are needed to confirm these benefits.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Dietary Fiber - Beta-carotene (Pro-Vitamin A) - Vitamin C - Potassium - Flavonoids - Triterpenoids
Reported Mechanism (Provisional)
Ivy gourd's triterpenoids (taraxerol, β-amyrin acetate, cucurbitacin B) and flavonoids (kaempferol, quercetin) inhibit digestive enzymes α-amylase and α-glucosidase, preventing rapid glucose absorption. The compounds enhance glucose uptake by promoting GLUT4 transporter recruitment to cell membranes while stimulating pancreatic β-cell regeneration and insulin secretion. Anti-inflammatory effects occur through COX-2 suppression and prostaglandin biosynthesis inhibition.
Clinical Narrative (Provisional)
Current evidence derives primarily from in vitro and animal studies, with no published human randomized controlled trials available. Laboratory studies demonstrate α-glucosidase inhibition with IC50 values of 0.75-77.66 μg/ml from leaf extracts. Animal studies show hepatoprotective effects at 250 mg/kg doses, reducing liver enzymes SGOT, SGPT, and ALP comparable to silymarin. Antipyretic activity was demonstrated at 200 mg/kg in rat fever models, though human clinical validation remains absent.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.